AUTO-8

N/A

Report date: 2025/07/01 15:17:22

Base Information

Drug NameAUTO-8

Drug Alias NameAUTO-8

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19Anti-BCMA

TargetsB-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAutolus Therapeutics Plc

China Registration ClassN/A

Develop Information

Active CompaniesUniversity College London

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A